[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 2 days · First seen · Last updated

Evotec clinical trial for orthopoxvirus antibodies

Overview

Evotec, through its subsidiary Just – Evotec Biologics, has initiated a Phase 1 clinical trial for JST-018. This investigational cocktail of monoclonal antibodies is designed to target orthopoxviruses, which include the viruses responsible for smallpox.

The program is part of the ‘Accelerated Antibodies Program’ initiated by the U.S. Department of War to expedite the delivery of therapeutic antibodies against viral threats. The development of JST-018 as a prophylactic therapy for military personnel involved antibody sequence selection, preclinical development, and manufacturing at the company’s J. POD® facility in Redmond, Washington, using a continuous bioprocessing platform.

Entities

Just – Evotec Biologics · Evotec SE · Asahi Kasei Corporation · Veloxis Pharmaceuticals · U.S. Department of War

Timeline

  1. 17 days ago

    [HEALTH] 2 sources
    Biotechnology firms advance clinical trials for viral and transplant therapies

    Biotech firms Evotec and OSE Immunotherapeutics report clinical progress: Evotec begins Phase I trials for an orthopoxvirus antibody, while OSE's partner Veloxis starts Phase II kidney transplant trials.

  2. 18 days ago

    [HEALTH] 2 sources
    Evotec Biologics starts Phase 1 trial for orthopoxvirus antibodies

    Just – Evotec Biologics has started a Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses developed under a U.S. Department of War program.

Sources

abcbourse.com · biotech-investments.com · evotec.com · kapitalmarktexperten.de